Ranolazine - Wikipedia, the free encyclopedia
Ranolazine, sold under the trade name Ranexa by Gilead Sciences (who acquired .... In addition, the new labeling states that Ranexa reduces hemoglobin A1c ...
http://en.wikipedia.org/wiki/Ranolazine...
|
Ranexa - do you use it, any side effects? - Discussion ...
I have been placed on Ranexa 500 mg daily for angina and since it's so new in the market, I'm afraid of taking it. I get back pain (below left shoulder ...
http://www.inspire.com/groups/womenheart/discussion/ranexa-d...
|
Ranexa™
Ranexa™ Supportive Slides. 18. SS-2. Exercise Duration at Trough at Wk 12 (LOCF) by Background Therapy CARISA (CVT 3033). Treatment by background therapy p ...
http://www.fda.gov/ohrms/dockets/AC/03/slides/4012S2_08_CVT-...
|
RANEXA | Industry information for RANEXA
Ranexa significantly reduced the frequency of angina attacks and significantly reduced the use of nitroglycerin in patients with chronic angina in clinical ...
http://www.medscape.com/infosite/ranexa...
|
Ranexa™
CE-1. Clinical Evaluation of Ranolazine Efficacy and Safety. Andrew A. Wolff, MD , FACC. Sr VP, Clinical Research and Development. CV Therapeutics, Inc. ...
http://www.fda.gov/ohrms/DOCKETS/ac/03/slides/4012S2_03_CVT-...
|
Products: Gilead
17 Dec 2004 ... Ranexa® (ranolazine) is an extended-release tablet for the treatment of chronic angina. Ranexa was approved in the United States in January ...
http://www.gilead.com/products...
|
Ranexa (ranolazine) Extended-Release Tablets
11 Jul 2009 ... Other (<0.5%) but potentially medically important adverse reactions observed more frequently in Ranexa than placebo treatment. ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-...
|
Ranolazine (Ranexa) for Chronic Angina - February 15, 2007 ...
15 Feb 2007 ... Ranolazine (Ranexa) represents a new class of drugs known as metabolic modulators. It is labeled for use in combination with amlodipine ...
http://www.aafp.org/afp/20070215/steps.html...
|
Ranexa™
CS-1. Clinical Evaluation of the Effects of Ranolazine on Ventricular Repolarization. Andrew A. Wolff, MD, FACC. Sr VP, Clinical Research and
Development ...
http://www.fda.gov/OHRMS/DOCKETS/ac/03/slides/4012S2_06_CVT-...
|
RANEXA | Industry information for RANEXA
Limit dose of Ranexa to 500 mg twice daily in patients on moderate CYP3A inhibitors, such as diltiazem, verapamil, aprepitant, erythromycin, fluconazole,
...
http://www.medscape.com/infosite/ranexa/article-7...
|
